نتایج جستجو برای: cap oseltamivir

تعداد نتایج: 24776  

2015
Kousuke Ohara Shinji Oshima Nanami Fukuda Yumiko Ochiai Ayumi Maruyama Aki Kanamuro Akio Negishi Seiichi Honma Shigeru Ohshima Masayuki Akimoto Shingo Takenaka Daisuke Kobayashi

Oseltamivir phosphate (OP) is used to treat influenza virus infections. However, its use may result in central nervous system (CNS) adverse effects. In Japan, OP is used with Kampo formulations to improve clinical effectiveness. We evaluated the potential for using Kampo formulations to reduce CNS adverse effects by quantifying the CNS distribution of oseltamivir and its active metabolite oselt...

Journal: :PLoS ONE 2008
Mai T. Q. Le Heiman F. L. Wertheim Hien D. Nguyen Walter Taylor Phuong V. M. Hoang Cuong D. Vuong Hang L. K. Nguyen Ha H. Nguyen Thai Q. Nguyen Trung V. Nguyen Trang D. Van Bich T. Ngoc Thinh N. Bui Binh G. Nguyen Liem T. Nguyen San T. Luong Phuc H. Phan Hung V. Pham Tung Nguyen Annette Fox Cam V. Nguyen Ha Q. Do Martin Crusat Jeremy Farrar Hien T. Nguyen Menno D. de Jong Peter Horby

BACKGROUND Prior to 2007, highly pathogenic avian influenza (HPAI) H5N1 viruses isolated from poultry and humans in Vietnam were consistently reported to be clade 1 viruses, susceptible to oseltamivir but resistant to amantadine. Here we describe the re-emergence of human HPAI H5N1 virus infections in Vietnam in 2007 and the characteristics of the isolated viruses. METHODS AND FINDINGS Respir...

2014
Marianne AB van der Sande Adam Meijer Fatmagül Şen-Kerpiclik Remko Enserink Herman JM Cools Piet Overduin José M Ferreira Marie-José Veldman-Ariessen

BACKGROUND Oseltamivir has been registered for use as post-exposition prophylaxis (PEP) following exposure to influenza, based on studies among healthy adults. Effectiveness among frail elderly nursing home populations still needs to be properly assessed. METHODS We conducted a randomised double-blind placebo-controlled trial of PEP with either oseltamivir (75 mg once daily) or placebo among ...

Journal: :MMWR. Morbidity and mortality weekly report 2009
S Pergam J Kuypers J Yager M Boeckh N Whittington E Whimbey T Uyeki V Deyde M Okomo - Adhiambo T Sheu A Trujillo A Klimov L Gubareva

Novel influenza A (H1N1) virus infection continues to cause illness and death among persons worldwide. Immunosuppressed patients with influenza virus infection can shed virus for prolonged periods, increasing the chances for development of drug resistance. On August 6, 2009, CDC detected evidence of resistance to the antiviral medication oseltamivir in two severely immunosuppressed patients wit...

Journal: :Journal of virology 2011
Maki Kiso Makoto Ozawa Mai Thi Quynh Le Hirotaka Imai Kei Takahashi Satoshi Kakugawa Takeshi Noda Taisuke Horimoto Yoshihiro Kawaoka

Like the histidine-to-tyrosine substitution at position 274 in neuraminidase (NA H274Y), an asparagine-to-serine mutation at position 294 in this protein (NA N294S) confers oseltamivir resistance to highly pathogenic H5N1 influenza A viruses. However, unlike viruses with the NA H274Y mutation, the properties of viruses possessing NA N294S are not well understood. Here, we assessed the effect of...

2012
Paula E. Miller Aksharananda Rambachan Roderick J. Hubbard Jiabai Li Alison E. Meyer Peter Stephens Anthony W. Mounts Melissa A. Rolfes Charles R. Penn

BACKGROUND The influenza A (H1N1) pandemic swept across the globe from April 2009 to August 2010 affecting millions. Many WHO Member States relied on antiviral drugs, specifically neuraminidase inhibitors (NAIs) oseltamivir and zanamivir, to treat influenza patients in critical condition. Such drugs have been found to be effective in reducing severity and duration of influenza illness, and like...

Journal: :Antiviral therapy 2010
Michèle Ottmann Maude Bouscambert Duchamp Jean-Sébastien Casalegno Emilie Frobert Vincent Moulès Olivier Ferraris Martine Valette Vanessa Escuret Bruno Lina

BACKGROUND With the recent emergence of the novel A(H1N1) virus in 2009, the efficacy of available drugs, such as neuraminidase (NA) inhibitors, is of great concern for good patient care. Influenza viruses are known to be able to acquire resistance. In 2007, A(H1N1) viruses related to A/Brisbane/59/2007 (H1N1) (A[H1N1] Brisbane-like virus), which are naturally resistant to oseltamivir, emerged....

2011
Silvio A. Ñamendys‐Silva Carolina Pérez‐Jiménez Patricia Cornejo‐Juárez Diana Vilar‐Compte Patricia Volkow

OBJECTIVE To describe the clinical course of a confirmed influenza A Pandemic (H1N1) 2009 virus infection in a patient with lymphoblastic lymphoma on chemotherapy. DESIGN Case report. SETTING Instituto Nacional de Cancerología located in Mexico City, a national referral center for cancer patients. PATIENT AND RESULTS A 15-year-old boy, with lymphoblastic lymphoma on chemotherapy. Oseltami...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2009
Takuo Ogihara Takashi Kano Tamae Wagatsuma Sho Wada Hikaru Yabuuchi Shigeki Enomoto Kaori Morimoto Yoshiyuki Shirasaka Shoko Kobayashi Ikumi Tamai

Oseltamivir, an ester-type prodrug of the neuraminidase inhibitor [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), has been developed for the treatment of A and B strains of the influenza virus but has neuropsychiatric and other side effects. In this study, we characterized the transport across intestinal epithelial cells and the absorption o...

2014
Yu Liu Yuhong Huang Baolin Wei Xinqiao Liu Yaqing Zhang Xiaomin Huang Yuping Tan Zengtao Sun

Objective. To evaluate the efficacy and safety of CHDI in the treatment of influenza infection. Method. A randomized double-blind, double dummy trial was conducted. Influenza patients with a positive influenza A rapid test diagnosis were randomized to receive CHDI or oseltamivir. Primary outcome was assessed by the median fever alleviation time and clearance time, and secondary outcome was tota...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید